Sagar Lonial

Sagar Lonial is a senior myeloma oncologist who has contributed to the clinical development of elotuzumab, daratumumab, and carfilzomib in multiple myeloma, establishing combination regimens that are now globally accepted standards. He led trials of KRd (carfilzomib-lenalidomide-dexamethasone) and participated in phase 3 studies of daratumumab-based quadruplets. His research addresses long-term treatment toxicities, management of high-risk myeloma, and novel targets for treatment-refractory disease. He is a frequent plenary speaker at ASH and ASCO and serves on international myeloma guideline panels.